| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.37 | 1e-14 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.32 | 1e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.26 | 1e-07 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.23 | 4e-06 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.16 | 7e-06 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-05 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.25 | 5e-05 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.15 | 5e-05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.2 | 8e-05 |